Abstract Pralsetinib (GAVRETO™, Blueprint Medicines Corporation) is a selective
rearranged during transfection (RET) inhibitor being developed for the treatment of various …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

The objective of this narrative review is to summarize the efficacy and safety of available
therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer …

Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET
gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy that originates in
parafollicular cells. It is well-known that a quarter of MTC are involved in hereditary multiple …

Purpose To evaluate whether postoperative circulating tumor DNA (ctDNA) in plasma of
patients with non-small cell lung cancer (NSCLC) can be used as a biomarker for early …

After the publication of the 2017 World Health Organization Classification of Head and Neck
Tumours, there has been increasing interest in the classification of newly categorized …

Background Rearranged during transfection (RET) is a targetable oncogene. RET fusions
have been reported in patients with metastatic colorectal cancer (mCRC). However, RET …

Context Medullary thyroid cancer (MTC) is usually caused by gain-of-function mutations in
the proto-oncogene RET. Objective This study aimed to determine the underlying …

Background Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET
fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with …